SOPH Healthcare

SOPHiA GENETICS SA

$6.91-2.81%

Price as of close on Nov 3, 2026 · Financials updated Sep 30, 2026

Basics

Sector: Healthcare
Industry: Health Information Services
Country: Switzerland
Market cap: 588.2M USD
Enterprise value: 438.4M USD
Full-time employees: 415

Overall health

Strength: growing faster than most peersgrowing faster than peers
Drawback: less profitable than most peersless profitable than peers
Drawback: its shares are priced higher than most peers relative to what it earnspriced higher than peers for its earnings
Drawback: higher risk than most peers: its share price swings more than most peers’ (beta 0.98 vs a peer median of 0.63), though less than the overall market and more debt relative to equity (1.01× vs a peer median of 0.22×)higher risk: bigger price swings (beta 0.98 vs peers 0.63) and more debt vs equity (1.01× vs peers 0.22×)

Ranks #1,063 of 1,157 healthcare companies (bottom 9%)

See how it ranks against its peers

Worth knowing

Stock-based pay is a large cost. Stock pay was 21% of revenue in 2025.
SOPHiA GENETICS paid employees $16M in stock in 2025, 21% of its $77M revenue. It doesn't use cash, so it flatters cash flow, but it is a real cost to shareholders through dilution.
Operating margin improving. Operating margin -92% in 2025, the best of the last 6 years, but the dollar loss grew to $71M from $67M.
SOPHiA GENETICS still lost money on operations in 2025. Revenue grew faster than costs, so the margin (-92%) was its best in the 6 years of filings we have, but the operating loss itself grew to $71M from $67M.
Valuation signals disagree. Cheaper than 50% of peers on free cash flow, but only 0% on earnings.
Relative to its free cash flow, SOPHiA GENETICS looks cheaper than 50% of peers; relative to its earnings, cheaper than only 0%. The valuation score blends the two, so look at which measure fits this business best.
Not profitable yet. Reported a loss in the 12 months to December 2025.
SOPHiA GENETICS reported a net loss over the last twelve months, so earnings-based measures can't show it as cheap.

StockQuotient Score

24/ 100

Oct 5 24 → Nov 4 24

Valuation

Is the price right?

8/100

Weak

3/3 inputs reported · High confidence

Since last quarter: No major changeValuation also moves with the share price every day.

Why

Weaker than most peers on:

▼ Earnings yield
▼ EBITDA yield

Compare with peers

Behind the score

Sector-normalized EBITDA, earnings, and free cash flow yields.

Earnings yield-16.7%

SEC filings (IFRS mapped) · 12 months to Dec 2025Negative (a loss or cash outflow), so it counts as zero whatever the share price30% base weight · Z-score -1.00Sector median: 0.0148 · MAD: 0.0148

EBITDA yield-13.2%

Yahoo Finance fallback · SEC enterprise value unavailable (debt or EBITDA not reported in standard form) · trailing 12 monthsNegative (a loss or cash outflow), so it counts as zero whatever the share price50% base weight · Z-score -1.00Sector median: 0.0401 · MAD: 0.0401

Free cash flow yield-7.7%

SEC filings (IFRS mapped) · 12 months to Dec 2025 · operating cash flow − capital spendingNegative (a loss or cash outflow), so it counts as zero whatever the share price20% base weight · Z-score 0.00Sector median: 0.0000 · MAD: 0.0000

Other data (not scored)

Book yield10.0%

SEC filings (IFRS mapped) · latest balance sheetReported valueInformational · 0% composite weightSector median: 0.3716 · MAD: 0.2313

Growth

Is it growing?

60/100

Moderate

3/3 inputs reported · High confidence

Since last quarter: ▲ Stronger

12-month revenue up 10.9%

Why

Stronger than most peers on:

▲ 3-yr revenue
▲ Revenue growth

Compare with peers

Behind the score

Revenue and earnings-per-share growth over one year, and revenue growth over three years.

Earnings per share growthUnavailable

The loss per share widened33% base weight · Z-score -1.20Sector median: 0.0976 · MAD: 0.2991

3-year revenue growth17.6%

SEC filings (IFRS mapped) · 3 years to Dec 2025Reported value33% base weight · Z-score 1.39Sector median: 0.0584 · MAD: 0.0840

Revenue growth18.6%

SEC filings (IFRS mapped) · 12 months to Dec 2025Reported value33% base weight · Z-score 1.28Sector median: 0.0609 · MAD: 0.0974

Profitability

Does it earn well?

10/100

Weak

3/3 inputs reported · High confidence

Since last quarter: ▲ Stronger

Operating margin rose 4.9 points to -91.8%

Why

Weaker than most peers on:

▼ ROIC
▼ ROA
▼ Operating margin

Compare with peers

Behind the score

Return on invested capital, operating margin, and return on assets.

Operating margin-91.8%

SEC filings (IFRS mapped) · 12 months to Dec 2025Reported value33% base weight · Z-score -8.12Sector median: 0.0706 · MAD: 0.1217

Return on assets-48.5%

SEC filings (IFRS mapped) · 12 months to Dec 2025Reported value33% base weight · Z-score -9.34Sector median: 0.0166 · MAD: 0.0537

Return on invested capital-227.8%

SEC filings (IFRS mapped) · 12 months to Dec 2025Outlier capped at sector 5th/95th percentile33% base weight · Z-score -16.87Sector median: 0.0471 · MAD: 0.1004

Other data (not scored)

Gross margin67.4%

SEC filings (IFRS mapped) · 12 months to Dec 2025Reported valueInformational · 0% composite weightSector median: 0.4697 · MAD: 0.2310

Return on equity-167.6%

SEC filings (IFRS mapped) · 12 months to Dec 2025Outlier capped at sector 5th/95th percentileInformational · 0% composite weightSector median: 0.0330 · MAD: 0.1225

Risk

Debt, liquidity, price swings

Higher

Higher relative risk

3/3 inputs reported · High confidence

Since last quarter: No major change

Why

Weaker than most peers on:

▼ Debt / equity
▼ Beta

Compare with peers

Behind the score

Relative to sector peers: 0 = lower relative risk · 1 = moderate · 2 = higher. Based on leverage, beta and liquidity.

Beta0.98

Yahoo Finance · 5-year monthly beta vs the marketReported value33% base weight · Z-score -1.06Sector median: 0.6250 · MAD: 0.3380

Current ratio1.96×

SEC filings (IFRS mapped) · latest balance sheetReported value33% base weight · Z-score -0.45Sector median: 2.5860 · MAD: 1.3850

Debt / equity1.01×

SEC filings (IFRS mapped) · latest balance sheetReported value33% base weight · Z-score -3.88Sector median: 0.2215 · MAD: 0.2039

Valuation, growth and profitability scores: higher is better. Risk: 0 is lower, 2 is higher. Risk is a relative proxy, not a bankruptcy probability. Scores depend on available sector peers.

Questions investors ask about SOPHiA GENETICS

Is SOPHiA GENETICS getting weaker?: Its latest SEC filing (Mar 3, 2026) got stronger: operating margin rose 4.9 points to -91.8%. Its overall score is unchanged at 24/100 since Oct 28, 2026.
How is SOPHiA GENETICS valued vs its peers?: Priced higher than most peers relative to what it earns. Valuation scores 8/100 against 1,393 healthcare peers. Earnings yield -16.7% vs a peer median of 1.5% (weaker than 100% of peers).Earnings yield -16.7% vs peers 1.5% (weaker than 100% of peers).
Is SOPHiA GENETICS growing?: Yes, faster than most of its peers. Growth scores 60/100 against 1,393 healthcare peers. 3-year revenue growth 17.6% vs a peer median of 5.8% (stronger than 78% of peers).3-year revenue growth 17.6% vs peers 5.8% (stronger than 78% of peers).
How profitable is SOPHiA GENETICS?: Less profitable than most of its peers. Profitability scores 10/100 against 1,393 healthcare peers. Return on invested capital -227.8% vs a peer median of 4.7% (weaker than 100% of peers).Return on invested capital -227.8% vs peers 4.7% (weaker than 100% of peers).
How risky is SOPHiA GENETICS?: Higher risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Debt / equity 1.01× vs a peer median of 0.22× (weaker than 81% of peers).Debt / equity 1.01× vs peers 0.22× (weaker than 81% of peers). A relative measure, not a bankruptcy probability.

Latest filing: what changed

Quarter ended Dec 31, 2025 · filed Mar 3, 2026 · compared with the quarter ended Jun 30, 2025

Got stronger

Operating margin rose 4.9 points to -91.8%

Worth watching: SOPHiA GENETICS is in the bottom fifth of its sector on profitability. From 2021 to 2025, 63% of companies in that position posted a loss over the following year, against 4% for the top fifth.

	Previous quarter	Latest quarter	Change
Revenue (12 months)	69.7M USD	77.3M USD	+10.9%
Net income (12 months)	−73.4M USD	−79.0M USD	+7.6%
Operating margin	-96.6%	-91.8%	+4.9 pts
Free cash flow (12 months)	−37.0M USD	−36.5M USD	−1.4%
Debt	47.5M USD	47.7M USD	+0.6%
Cash	94.8M USD	70.3M USD	−25.9%

From the company’s own SEC filings, as filed. Twelve-month figures roll forward one quarter at a time.

Financials

Fiscal years from SEC annual filings · change vs the prior year

Key ratios	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	Change
Gross margin	62.4%	65.7%	68.8%	67.4%	67.4%	▼ 0.0 pts
Operating margin	-176.7%	-184.7%	-120.0%	-102.1%	-91.8%	▲ 10 pts
Net margin	-182.1%	-183.9%	-126.6%	-95.9%	-102.2%	▼ 6.3 pts
Return on assets (ROA)	-23.0%	-35.9%	-38.3%	-40.2%	-48.5%	▼ 8.2 pts
Return on equity (ROE)	-26.8%	-43.7%	-52.2%	-64.8%	-167.6%	▼ 103 pts
Free cash flow margin	-149.9%	-156.0%	-87.7%	-68.7%	-47.2%	▲ 21 pts
Current ratio	9.89×	7.32×	4.16×	3.71×	1.96×	▼ 47%
Quick ratio	9.69×	7.13×	3.97×	3.49×	1.84×	▼ 47%
Debt to equity	0.00×	—	0.00×	0.14×	1.01×	▲ 638%
Interest coverage	-108.65×	-137.44×	-127.26×	-34.80×	-15.57×	▲ 55%

SOPH price history

Price history is added with the daily price update and will appear after the next one.

Similar companies

Sector leaderboards

BB Biotech AGBBZA.DE100/ 100

Arbutus Biopharma CorporationABUS97/ 100

Q32 Bio Inc.QTTB97/ 100

Bringing the fundamentals into focus…

Overall health

Strength: growing faster than most peersgrowing faster than peers

Drawback: less profitable than most peersless profitable than peers

Drawback: its shares are priced higher than most peers relative to what it earnspriced higher than peers for its earnings

Drawback: higher risk than most peers: its share price swings more than most peers’ (beta 0.98 vs a peer median of 0.63), though less than the overall market and more debt relative to equity (1.01× vs a peer median of 0.22×)higher risk: bigger price swings (beta 0.98 vs peers 0.63) and more debt vs equity (1.01× vs peers 0.22×)

Ranks #1,063 of 1,157 healthcare companies (bottom 9%)

See how it ranks against its peers

Worth knowing

Stock-based pay is a large cost. Stock pay was 21% of revenue in 2025.

SOPHiA GENETICS paid employees $16M in stock in 2025, 21% of its $77M revenue. It doesn't use cash, so it flatters cash flow, but it is a real cost to shareholders through dilution.

Operating margin improving. Operating margin -92% in 2025, the best of the last 6 years, but the dollar loss grew to $71M from $67M.

SOPHiA GENETICS still lost money on operations in 2025. Revenue grew faster than costs, so the margin (-92%) was its best in the 6 years of filings we have, but the operating loss itself grew to $71M from $67M.

Valuation signals disagree. Cheaper than 50% of peers on free cash flow, but only 0% on earnings.

Relative to its free cash flow, SOPHiA GENETICS looks cheaper than 50% of peers; relative to its earnings, cheaper than only 0%. The valuation score blends the two, so look at which measure fits this business best.

Not profitable yet. Reported a loss in the 12 months to December 2025.

SOPHiA GENETICS reported a net loss over the last twelve months, so earnings-based measures can't show it as cheap.

Questions investors ask about SOPHiA GENETICS

Is SOPHiA GENETICS getting weaker?

Its latest SEC filing (Mar 3, 2026) got stronger: operating margin rose 4.9 points to -91.8%. Its overall score is unchanged at 24/100 since Oct 28, 2026.

How is SOPHiA GENETICS valued vs its peers?

Priced higher than most peers relative to what it earns. Valuation scores 8/100 against 1,393 healthcare peers. Earnings yield -16.7% vs a peer median of 1.5% (weaker than 100% of peers).Earnings yield -16.7% vs peers 1.5% (weaker than 100% of peers).

Is SOPHiA GENETICS growing?

Yes, faster than most of its peers. Growth scores 60/100 against 1,393 healthcare peers. 3-year revenue growth 17.6% vs a peer median of 5.8% (stronger than 78% of peers).3-year revenue growth 17.6% vs peers 5.8% (stronger than 78% of peers).

How profitable is SOPHiA GENETICS?

Less profitable than most of its peers. Profitability scores 10/100 against 1,393 healthcare peers. Return on invested capital -227.8% vs a peer median of 4.7% (weaker than 100% of peers).Return on invested capital -227.8% vs peers 4.7% (weaker than 100% of peers).

How risky is SOPHiA GENETICS?

Higher risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Debt / equity 1.01× vs a peer median of 0.22× (weaker than 81% of peers).Debt / equity 1.01× vs peers 0.22× (weaker than 81% of peers). A relative measure, not a bankruptcy probability.

Previous quarter

Latest quarter

Change

Revenue (12 months)

69.7M USD

77.3M USD

+10.9%

Net income (12 months)

−73.4M USD

−79.0M USD

+7.6%

Operating margin

-96.6%

-91.8%

+4.9 pts

Free cash flow (12 months)

−37.0M USD

−36.5M USD

−1.4%

Debt

47.5M USD

47.7M USD

+0.6%

Cash

94.8M USD

70.3M USD

−25.9%

Key ratios

FY 2021

FY 2022

FY 2023

FY 2024

FY 2025

Change

Gross margin

62.4%

65.7%

68.8%

67.4%

▼ 0.0 pts

Operating margin

-176.7%

-184.7%

-120.0%

-102.1%

-91.8%

▲ 10 pts

Net margin

-182.1%

-183.9%

-126.6%

-95.9%

-102.2%

▼ 6.3 pts

Return on assets (ROA)

-23.0%

-35.9%

-38.3%

-40.2%

-48.5%

▼ 8.2 pts

Return on equity (ROE)

-26.8%

-43.7%

-52.2%

-64.8%

-167.6%

▼ 103 pts

Free cash flow margin

-149.9%

-156.0%

-87.7%

-68.7%

-47.2%

▲ 21 pts

Current ratio

9.89×

7.32×

4.16×

3.71×

1.96×

▼ 47%

Quick ratio

9.69×

7.13×

3.97×

3.49×

1.84×

▼ 47%

Debt to equity

0.00×

—

0.00×

0.14×

1.01×

▲ 638%

Interest coverage

-108.65×

-137.44×

-127.26×

-34.80×

-15.57×

▲ 55%